Patents by Inventor AJ Robert MCGRAY

AJ Robert MCGRAY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12767708
    Abstract: Described herein are antibodies that block the function of periostin. Also described herein are their uses in treating cancer and modifying tumor immune properties.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: October 20, 2026
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Arif Jetha, Johan Fransson, Aj Robert Mcgray, Joanne Hulme
  • Publication number: 20260077046
    Abstract: Provided is a method of treating cancer in an individual by administering to the individual modified cells that express a chimeric antigen receptor (CAR) that contain a TIGIT extracellular domain that can bind to poliovirus receptor (PVR), a CD28 segment, and a CD3? segment. The modified cells may co-express and secrete a Bi-specific T cell engager (BiTE). The BiTE includes a segment that can specifically bind to human Folate Receptor alpha (FR?) and a segment that that can specifically bind to a human CD3? segment. Modified cells that express the CAR, and may also express and secrete the BiTE, and polynucleotides encoding the CAR and the BiTE, are also provided.
    Type: Application
    Filed: October 27, 2025
    Publication date: March 19, 2026
    Inventors: AJ Robert McGray, Jessie Chiello
  • Patent number: 12453772
    Abstract: Provided is a method of treating cancer in an individual by administering to the individual modified cells that express a chimeric antigen receptor (CAR) that contain a TIGIT extracellular domain that can bind to poliovirus receptor (PVR), a CD28 segment, and a CD3? segment. The modified cells may co-express and secrete a Bi-specific T cell engager (BiTE). The BiTE includes a segment that can specifically bind to human Folate Receptor alpha (FR?) and a segment that that can specifically bind to a human CD3? segment. Modified cells that express the CAR, and may also express and secrete the BiTE, and polynucleotides encoding the CAR and the BiTE, are also provided.
    Type: Grant
    Filed: December 23, 2024
    Date of Patent: October 28, 2025
    Assignee: Roswell Park Cancer Institute Corporation
    Inventors: AJ Robert McGray, Jessie Chiello
  • Publication number: 20250205336
    Abstract: Provided is a method of treating cancer in an individual by administering to the individual modified cells that express a chimeric antigen receptor (CAR) that contain a TIGIT extracellular domain that can bind to poliovirus receptor (PVR), a CD28 segment, and a CD3? segment. The modified cells may co-express and secrete a Bi-specific T cell engager (BiTE). The BiTE includes a segment that can specifically bind to human Folate Receptor alpha (FR?) and a segment that that can specifically bind to a human CD3? segment. Modified cells that express the CAR, and may also express and secrete the BiTE, and polynucleotides encoding the CAR and the BiTE, are also provided.
    Type: Application
    Filed: December 23, 2024
    Publication date: June 26, 2025
    Inventors: AJ Robert McGray, Jessie Chiello
  • Publication number: 20230030597
    Abstract: Described herein are methods of treating cancer comprising administering to the individual (a) a PD-1 axis inhibitor; and (b) an inhibitor of periostin.
    Type: Application
    Filed: August 27, 2020
    Publication date: February 2, 2023
    Inventors: Arif JETHA, Johan FRANSSON, AJ Robert MCGRAY, Joanne HULME
  • Publication number: 20220010003
    Abstract: Described herein are antibodies that block the function of periostin. Also described herein are their uses in treating cancer and modifying tumor immune properties.
    Type: Application
    Filed: December 13, 2019
    Publication date: January 13, 2022
    Inventors: Arif JETHA, Johan FRANSSON, AJ Robert MCGRAY, Joanne HULME